ccRCC is recognized as one of the more responsive tumors to immunotherapy, and mTOR has been reported to be participate in tumor immunity (Posadas, Limvorasak & Figlin, 2017; Saxton & Sabatini, 2017). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.